Specialty drugs do not behave like primary care drugs in pricing benchmark data, and the analytical frameworks that work for Lipitor analogs require significant modification before they apply to a CAR-T therapy or an enzyme replacement for a lysosomal storage disorder. The market conditions are different—smaller patient populations, fewer payer relationships, less formulary competition, different channel economics—in ways that systematically alter the WAC-ASP spread dynamics that MedPricer’s cross-dataset analysis depends upon. Understanding where the benchmark signal is informative and where it is misleading is prerequisite to using the data responsibly.
Specialty Market Channel Economics
A primary care drug moving through retail pharmacy networks encounters PBM formulary decisions affecting millions of patients. The rebate economics of those decisions dominate the WAC-ASP spread. A specialty drug administered in an outpatient oncology clinic or infusion center operates in a different channel: Part B reimbursement at ASP plus 6%, physician-administered, with formulary decisions made at the institution level rather than through commercial PBM tier structures.
The gross-to-net dynamics in this channel are fundamentally different. Manufacturer rebates to PBMs play a much smaller role. 340B pricing obligations play a larger one, since oncology centers and cancer hospitals are frequently 340B covered entities with high drug acquisition volumes. Patient assistance programs, copay accumulators, and specialty pharmacy arrangements add additional complexity. The WAC-ASP spread for a Part B oncology drug contains these signals mixed together, with no clean way to attribute the spread to specific mechanisms from external data.
Rare Disease Pricing and the ASP Problem
For drugs targeting rare or ultra-rare diseases—conditions affecting fewer than 200,000 patients in the United States—the ASP calculation itself becomes methodologically problematic. ASP is based on manufacturer-reported unit sales across all channels. For a drug with annual sales of 2,000 units, the ASP calculation is based on a very small sales volume, making it highly sensitive to a small number of large transactions, government program pricing requirements, and compassionate use arrangements.
The statistical instability of ASP for small-population drugs means that WAC-ASP spread analysis is unreliable for rare disease products. Quarter-to-quarter ASP volatility may reflect a single large government procurement rather than any genuine pricing trend. MedPricer’s dataset is most analytically powerful for drugs with large sales volumes where the ASP calculation averages across many transactions—the population of drugs for which the law of large numbers makes the average meaningful.
Gene Therapy Pricing and the Coming Benchmark Challenge
One-time gene therapies present a structurally novel challenge for any pricing benchmark system. WAC, ASP, and NADAC were designed for chronic therapy drugs with regular, ongoing dispensing. A drug administered once, potentially curing the condition, with a list price between one and three million dollars, does not fit cleanly into any of these benchmark frameworks.
CMS has begun developing payment models for gene therapies that include outcomes-based arrangements and installment payment options—structures that have no analog in the rebate-and-dispensing-fee economics that WAC, ASP, and NADAC were designed to track. The benchmark data that exists for approved gene therapies is sparse, methodologically complex, and not directly comparable across products. MedPricer’s infrastructure will need to evolve to handle these novel pricing structures as gene therapy approvals accelerate.
Where Specialty Benchmark Analysis Does Add Value
None of this means that benchmark analysis is useless for specialty drugs—it means the use cases are more specific. Tracking ASP trajectories for oncology drugs as biosimilar or biosimilar-adjacent competitors enter the market provides useful competitive intelligence. Monitoring NADAC for specialty pharmacy products as they transition from branded to generic status reveals acquisition cost trends relevant to specialty pharmacy operators. Comparing WAC-ASP spreads across oncology drugs within the same therapeutic class reveals differences in PBM rebate arrangements that may reflect differential formulary positioning.
Those are real analytical applications, even if they require more contextual interpretation than the same analysis applied to primary care drugs. The caveat is not that specialty drug benchmark analysis is impossible—it is that the interpretive framework must be tailored to specialty market conditions rather than borrowed wholesale from primary care pricing analysis.
